Sullivan Christopher Ryan

Chief Financial OfficerAvalo Therapeutics, Inc. (AVTX) · full profile →Form 4 · filed Aug 19, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$1.5M
Net Open-Market Flow
-$1.5M
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 18, 2026Option exercise(M)31K$9.88$307K71K
Aug 18, 2026Sell(S)31K$20.05$622K40K
Aug 17, 2026Sell(S)38K$19.85$753K44K
Aug 17, 2026Sell(S)4K$19.94$75K40K
Aug 17, 2026Option exercise(M)38K$9.88$375K79K
Aug 17, 2026Option exercise(M)3K$9.88$28K82K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 18, 2026Option exercise(M)31K$096K
Aug 17, 2026Option exercise(M)38K$0130K
Aug 17, 2026Option exercise(M)3K$0127K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001810417-26-000019) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

Build

Build on these Form 4 transactions

The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.